

Advanced
Nanoformulations
Theranostic Nanosystems,
Volume 3

Advanced Nanoformulations

Theranostic Nanosystems, Volume 3

Edited by

Md Saquib Hasnain

*Department of Pharmacy, Palamau Institute of Pharmacy,
Daltonganj, Jharkhand, India*

Amit Kumar Nayak

*Department of Pharmaceutics, Seemanta Institute of
Pharmaceutical Sciences, Mayurbhanj, Odisha, India*

Tejraj M. Aminabhavi

*School of Advanced Sciences, KLE Technological University,
Hubballi, Karnataka, India*



ELSEVIER



ACADEMIC PRESS

An imprint of Elsevier

Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom

Copyright © 2023 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-323-85785-7

For Information on all Academic Press publications
visit our website at <https://www.elsevier.com/books-and-journals>

Publisher: Stacy Masucci
Acquisitions Editor: Andre Gerhard Wolff
Editorial Project Manager: Howi M. De Ramos
Production Project Manager: Swapna Srinivasan
Cover Designer: Victoria Pearson

Typeset by MPS Limited, Chennai, India



Contents

List of contributors	xxi
Preface	xxix

CHAPTER 1 Advanced nanoformulations for theranostics: current status and challenges..... 1

*Aalok Basu, Md Saquib Hasnain,
Amit Kumar Nayak and Tejraj M. Aminabhavi*

1.1 Introduction	1
1.2 Nanoformulations as potential theranostic agents	2
1.3 Clinical status of nanotheranostics in disease management.....	4
1.3.1 Cancer.....	4
1.3.2 Autoimmune diseases	6
1.3.3 Neurodegenerative diseases	8
1.3.4 Cardiovascular diseases	9
1.3.5 Bacterial infections	10
1.4 Challenges related to the transport of nanotheranostics.....	11
1.5 Conclusions and future perspectives.....	13
References.....	13

CHAPTER 2 Chitosan-based nanosuspensions for ocular diagnosis and therapy 21

Agustina Alaimo and Oscar E. Pérez

2.1 Introduction	21
2.2 Chitosan, the “biopolymer of the 21st century”	23
2.3 Chitosan at the service of nanotechnology	26
2.4 Methodologies for chitosan-based nanosuspension synthesis.....	27
2.5 The eye is “the sensory organ responsible for the visual perception of the world”	28
2.5.1 Anatomy	28
2.5.2 Natural ocular barriers	29
2.5.3 Administration routes in ophthalmology	31
2.6 Chitosan-based nanosuspension for ocular therapy and diagnosis	32
2.6.1 Glaucoma	32
2.6.2 Ocular infection caused by microorganisms	36
2.6.3 Ocular inflammation	40
2.6.4 Others	43
2.7 Conclusions	45

Acknowledgments	46
References.....	46
CHAPTER 3 Nanoemulsions in theranostics	51
<i>Shannon Priscilla Callender and Shawn Wettig</i>	
3.1 Introduction to emulsion systems	51
3.2 “Nano” emulsion systems	52
3.3 Nano- and microemulsion use in theranostics.....	53
3.4 Advantages of nano- and microemulsions in theranostic applications.....	56
3.4.1 Droplet size	56
3.4.2 Starting ingredients	56
3.4.3 Stability	57
3.4.4 Delivery of hydrophilic and hydrophobic compounds.....	57
3.5 Design and development of theranostic nanoemulsions	57
3.5.1 Surfactant choice.....	58
3.5.2 Oil choice	59
3.5.3 Type of compound for encapsulation and delivery.....	60
3.5.4 Targeted delivery	62
3.6 Applications of nano- and microemulsions in theranostics	63
3.7 Diagnostic purposes	63
3.7.1 Metals.....	63
3.8 Fluorescent materials.....	67
3.9 Sonic-sensitive materials.....	69
3.10 Targeting purposes	72
3.10.1 Proteins, peptides, and antibodies.....	72
3.10.2 Lipids.....	73
3.10.3 Polymers.....	73
3.11 The future of nano- and microemulsion technology in theranostic applications.....	74
References.....	75
CHAPTER 4 Self-nanoemulsifying systems for drug delivery therapeutics	81
<i>Omar A. Abdel Aziz, Ahmed S. Abo Dena and Ibrahim M. El-Sherbiny</i>	
4.1 Introduction	81
4.2 Life applications and market updates	84
4.3 Types of nanoemulsions.....	85
4.3.1 General structure of the emulsion systems.....	85
4.3.2 Polymer-based emulsion systems	86

4.3.3	Solvents and cosolvents	86
4.3.4	Surfactants and cosurfactants.....	86
4.4	Chemical preparation methods of nanoemulsion systems	87
4.4.1	High-energy methods.....	87
4.4.2	Low-energy methods.....	88
4.5	Characterization of nanoemulsion systems	89
4.5.1	Zeta potential	89
4.5.2	Particle size and polydispersity	89
4.5.3	Electron microscopy	90
4.5.4	Ultraviolet-visible spectroscopy	90
4.6	Applications of nanoemulsion systems.....	91
4.6.1	Drug delivery	91
4.6.2	Polymeric nanoemulsion-modified drugs.....	91
4.6.3	Cosmetics	92
	Further reading	93
CHAPTER 5	Polymeric micelles for therapeutics and diagnosis	97
	<i>Maria Karayianni, Angeliki Chroni, Varvara Chrysostomou, Despoina Giaouzi, Martha Kafetzi, Dimitris Selianitis, Theodore Sentoukas and Stergios Pispas</i>	
5.1	Introduction	97
5.2	General characteristics of block copolymer micelles.....	100
5.3	Micellar systems for therapy.....	105
5.3.1	Micelles encapsulating low molecular weight hydrophobic drugs.....	107
5.3.2	Micellar systems for gene delivery and therapy	116
5.3.3	Micellar systems for protein delivery.....	125
5.3.4	Micelles for photodynamic therapy and hyperthermia.....	132
5.4	Micellar systems for bioimaging	136
5.4.1	Magnetic resonance imaging	136
5.4.2	Optical imaging.....	143
5.5	Conclusions	145
	References.....	145
CHAPTER 6	Dendrimers for theranostic applications	159
	<i>Søren Leth Mejlsøe and Jørn B. Christensen</i>	
6.1	Introduction	159
6.2	Covalent dendrimer-based theranostic systems.....	162
6.3	Self-assembled dendrimer-based theranostic systems.....	168

6.4	Theranostic systems based on dendrimers or dendrons bound to a nanoparticle.....	173
6.5	Outlook	177
	References.....	177
CHAPTER 7	Nanogels as theranostic platforms: drug delivery, targeting, and imaging	181
	<i>Aristeidis Papagiannopoulos and Evdokia Stefanopoulou</i>	
7.1	Introduction	181
7.2	Structure and properties of nanogels	183
	7.2.1 Preparation of nanogels	183
	7.2.2 Morphology of nanogels.....	185
7.3	Nanogels for theranostic applications.....	187
	7.3.1 Nanogels based on natural polymers.....	189
	7.3.2 Nanogels based on synthetic polymers	196
	7.3.3 Nanogels based on synthetic copolymers or natural/synthetic polymer hybrids	199
7.4	Conclusion and future perspective.....	202
	References.....	203
CHAPTER 8	Nanocrystals as a versatile platform for theranostic applications.....	209
	<i>Thashree Marimuthu, Lisa C. du Toit and Yahya E. Choonara</i>	
8.1	Introduction	209
8.2	Versatile platform development.....	209
	8.2.1 Drug delivery platforms with enhanced solubility.....	210
	8.2.2 Targeted drug delivery platforms	213
	8.2.3 Theranostic platforms	215
8.3	Theranostic applications of nanocrystals.....	219
	8.3.1 Chemotheranostics	220
	8.3.2 Photodynamic therapy and photothermal therapy theranostics.....	225
	8.3.3 Other applications of nanocrystal platforms in theranostics.....	228
8.4	Conclusions and outlook	228
	References.....	232
CHAPTER 9	Niosome as a promising vesicular tool for therapy and diagnosis	241
	<i>Amit Verma, Pritish Kumar Panda and Sanjay K. Jain</i>	
9.1	Introduction	241

9.2	Benefits of niosomes over other carriers	242
9.3	Formulation considerations for niosomes	242
9.3.1	Role of nonionic surfactants	242
9.3.2	Role of cholesterol	244
9.3.3	Role of charged molecules	244
9.4	Development of niosomes	245
9.4.1	Vesicle preparation	245
9.4.2	Methods of preparation	245
9.5	Loading of the drug in niosomes	249
9.5.1	Direct entrapment (passive loading)	249
9.5.2	Remote loading (active loading)	249
9.6	Vesicle purification	250
9.6.1	Dialysis	250
9.6.2	Gel filtration	250
9.6.3	Centrifugation/ultracentrifugation	250
9.7	Characterization of niosomes	251
9.7.1	Entrapment efficiency	251
9.7.2	Vesicle size and shape	252
9.7.3	Osmotic shock	252
9.7.4	Determination of viscosity	252
9.7.5	In vitro release	252
9.7.6	Stability and toxicity studies	252
9.8	Application of niosomes in different drug delivery systems	253
9.8.1	Niosomes in oral drug delivery	253
9.8.2	Niosomes in ocular drug delivery	253
9.8.3	Niosomes in dermal and transdermal drug delivery	254
9.9	Application of niosomes in targeting	255
9.9.1	Niosomes in cancer targeting	255
9.9.2	Niosomes for brain targeting	256
9.9.3	Niosomes for lungs targeting	256
9.10	Conclusion and prospects	257
	References	257

CHAPTER 10 Cubosomes for enhanced drug delivery and targeting therapeutics 263

*Hadeer M. Abdelaziz, Sarah Mokhtar, Doaa M. Anwar,
Sherine N. Khattab, Kadria A. Elkhodairy and
Ahmed O. Elzoghby*

10.1	Introduction	263
10.2	Narration/the past	265
10.3	Theories of the self-assembling of amphiphilic lipids	265

10.4	Components of cubosomes	266
10.4.1	Amphiphilic lipids	266
10.4.2	Stabilizers	266
10.5	Manufacture of cubosomes	267
10.5.1	Top-down technique	268
10.5.2	Bottom-up approach.....	268
10.6	Applications of cubosomes in drug delivery	268
10.6.1	Ocular applications	269
10.6.2	Oral applications	271
10.6.3	Transdermal applications	272
10.6.4	Transnasal applications	274
10.6.5	Anticancer applications.....	275
10.6.6	Gene therapy	280
10.6.7	Theranostics	281
10.6.8	Nanocosmeceuticals.....	283
10.7	Conclusion and future perspective.....	283
	References.....	284

CHAPTER 11 Aquasomes: a novel nanocarrier system for drug delivery 289

Gwaza Eric Ayom, Nyemaga Masanje Malima, Shesan John Owonubi and Neerish Revaprasadu

11.1	Introduction	289
11.2	Composition of aquasomes	291
11.2.1	Inner core material	291
11.3	Polyhydroxyl carbohydrate layer	291
11.4	Outer layer.....	291
11.5	Preparation of aquasomes	292
11.6	Preparation of the inner core material	292
11.7	Coating of the inner core with polyhydroxy carbohydrate	293
11.8	Loading of the bioactive agent or drug	293
11.9	Properties of aquasomes.....	293
11.10	Characterization of aquasomes	294
11.11	Particle size and distribution.....	294
11.12	Particle crystallinity	294
11.13	Particle structure.....	295
11.14	Polyhydroxy carbohydrate coating	295
11.15	Drug loading of aquasomes	296
11.15.1	Drug release efficiency of aquasomes.....	297
11.16	Zeta potential measurements of aquasomes	297
11.17	Formulation of aquasomes	297

11.18	Applications of aquasomes as a system for drug delivery.....	298
11.19	Antigen nanocarriers	299
11.20	Insulin carrier	300
11.21	Oxygen carrier.....	301
11.22	Drug carrier	302
11.23	Fate of aquasomes.....	303
11.24	Conclusion.....	305
	Acknowledgments	305
	References.....	305
CHAPTER 12	Nanostructured lipid carriers: a novel platform for therapeutics.....	311
	<i>Poonam Parashar and Jovita Kanoujia</i>	
12.1	Introduction	311
12.2	Therapeutic exhibitions of nanostructured lipid carriers.....	313
12.2.1	Nanostructured lipid carriers in cancer theranostics.....	314
12.2.2	Nanostructured lipid carriers in cardiovascular system.....	316
12.2.3	Nanostructured lipid carriers in central nervous system.....	317
12.2.4	Nanostructured lipid carriers in gastrointestinal tract disorders	319
12.2.5	Nanostructured lipid carriers in diabetes mellitus.....	320
12.2.6	Nanostructured lipid carriers in dermatological disorders	321
12.2.7	Nanostructured lipid carriers in ocular ailments	324
12.2.8	Nanostructured lipid carriers in renal disorders.....	324
12.2.9	Nanostructured lipid carriers in wound healing	325
12.2.10	Nanostructured lipid carriers in pulmonary disorders	325
12.2.11	Miscellaneous applications	326
12.3	Marketed product of nanostructured lipid carriers	326
12.4	Patents related to nanostructured lipid carrier	326
12.5	Conclusions and future perspectives.....	334
	References.....	334
CHAPTER 13	Self-assembled protein-drug nanoparticles for enhanced drug delivery and targeting cancer therapeutics	341
	<i>Islam A. Hassanin, Mohamed Teleb, Adnan A. Bekhit, Kadria A. Elkhodairy, Sherine N. Khattab and Ahmed O. Elzoghby</i>	
13.1	Introduction	341

13.2	Fabrication methods of self-assembled protein nanoparticles	342
13.2.1	Desolvation.....	344
13.2.2	Noncovalent self-assembly of protein nanoparticles	345
13.2.3	Chemical conjugation	350
13.3	Factors affecting the formation of self-assembled protein nanoparticles.....	350
13.3.1	Protein concentration	350
13.3.2	Protein/drug ratio	351
13.3.3	Temperature	351
13.3.4	pH.....	352
13.4	Implications of the self-assembled protein nanoparticles	352
13.4.1	Targeted drug delivery to tumors and enhanced cellular uptake	352
13.4.2	Enhanced cytotoxicity.....	353
13.4.3	Improved stability	353
13.4.4	Enhanced pharmacokinetics.....	353
13.4.5	Nanotheranostic applications.....	354
13.4.6	Reduced toxicity	354
13.4.7	Stimuli-responsive drug release.....	354
13.4.8	Overcoming cancer drug resistance.....	356
13.5	Conclusion	356
	References.....	357
CHAPTER 14	Stimuli-responsive nanosystems as smart nanotheranostics.....	363
	<i>Micaela A. Macchione and Miriam C. Strumia</i>	
14.1	Introduction	363
14.2	Plasmonic-based nanotheranostics.....	369
14.3	Silica and zeolite-based nanotheranostics	373
14.4	Magnetic-based nanotheranostics	376
14.5	Carbon-based nanotheranostics.....	378
14.6	Multicomponent nanotheranostics	382
14.7	Conclusion and perspectives.....	387
	References.....	388
CHAPTER 15	Nanoconjugates and nanoconjugate formulations for improving drug delivery and therapeutic efficacy	397
	<i>Ana R. Neves, Swati Biswas, Ângela Sousa and Diana Costa</i>	
15.1	Introduction	397
15.1.1	Nanoconjugation	398

15.2	Drug delivery.....	402
15.2.1	Strategies to improve drug solubility	402
15.2.2	Responsive drug release.....	404
15.2.3	Targeting	406
15.2.4	Codelivery	409
15.3	Biomedical applications.....	412
15.3.1	Cancer therapy	415
15.4	Concluding remarks	419
	References.....	420

CHAPTER 16 Nanophytomedicines: a novel approach for improving therapeutics via delivery of herbal medicine..... 431

Saad Bakrim, Abdelaali Balahbib, Hanae Naceiri Mrabti, Rokia Ghchime, Nasreddine El Omari and Abdelhakim Bouyahya

16.1	Introduction	431
16.2	Human skin	432
16.2.1	Epidermis	433
16.2.2	Dermis	434
16.3	Drug penetration.....	436
16.3.1	Transepidermal pathway.....	437
16.3.2	Appendageal pathway.....	437
16.4	Nanocarriers	437
16.5	Methods used in the formulation of nanophytomedicines	438
16.5.1	Nanoliposomes	439
16.5.2	Nanoemulsions	440
16.5.3	Transferosomes	441
16.5.4	Niosomes	441
16.5.5	Ethosomes	442
16.5.6	Dendrimers	442
16.5.7	Nanoparticles.....	443
16.5.8	Phytosomes.....	443
16.5.9	Cyclodextrins	444
16.6	Applications of nanophytomedicines.....	445
16.6.1	Nanophytomedicines as anticancer drugs	445
16.6.2	Nanophytomedicines as antidiabetic drugs	446
16.6.3	Anti-schistosomal activity	448
16.6.4	Leishmanicidal activity.....	449
16.6.5	Larvicidal and insecticidal activity.....	449
16.6.6	Schizophrenia and psychic disorders.....	451

16.7	Combination of antipsychotics with herbal drugs.....	452
16.8	Nanotechnology for combinational delivery of antipsychotics	454
16.9	Perspectives and conclusions	454
	References.....	455
CHAPTER 17	Multifunctional nanocomposites for theranostics.....	467
	<i>Luiza Steffens Reinhardt, Mabilly Cox Holanda de Barros Dias and Dinara Jaqueline Moura</i>	
17.1	Introduction	467
17.2	Nanocomposites	467
17.3	The dual approach of theranostics	469
	17.3.1 Nanocomposites for theranostics	472
17.4	Perspectives	495
	References.....	495
CHAPTER 18	Nanofibers for diagnosis, drug delivery, and therapy.....	503
	<i>Nadun H. Madanayake and Nadeesh M. Adassooriya</i>	
18.1	Introduction	503
18.2	Classification of nanofibers	504
18.3	Nanofiber fabricating techniques	506
	18.3.1 Thermally induced phase separation	506
	18.3.2 Template synthesis.....	506
	18.3.3 Drawing	506
	18.3.4 Chemical vapor deposition	507
	18.3.5 Electrospinning	507
18.4	Nanofibers in drug delivery	507
18.5	Nanofibers in disease diagnosis.....	509
18.6	Nanofibers in therapeutic applications	510
18.7	Conclusion and future perspectives	511
	References.....	512
CHAPTER 19	Nanovectors for theranostic applications	519
	<i>Sabeerabi Bonala, Sri Amrutha Sankaranarayanan and Aravind Kumar Rengan</i>	
19.1	Introduction	519
19.2	Features of nanovectors	521
19.3	History of nanovectors	524
	19.3.1 First generation nanovectors.....	524
	19.3.2 Second generation nanovectors	524
	19.3.3 Third generation nanovectors	525

19.3.4	Inorganic nanovectors.....	525
19.3.5	Organic nanovectors.....	532
19.3.6	Biomimetics nanovectors.....	536
19.3.7	Clinical translation of nanovectors.....	542
19.4	Conclusion.....	544
	References.....	545
CHAPTER 20	Nanoprobes for advanced nanotheranostic applications.....	557
	<i>Mansab Ali Saleemi and Eng Hwa Wong</i>	
20.1	Introduction.....	557
20.2	Theranostic nanomedicine.....	559
20.3	Gold nanoparticles.....	559
20.4	Drug-polymer conjugates.....	561
20.5	Carbon nanomaterials.....	563
20.6	Polymeric nanoparticles.....	564
20.7	Dendrimers.....	567
20.8	Micelles.....	569
20.9	Liposomes.....	570
20.10	Solid lipid nanoparticles.....	573
20.11	Modular development of hybrid nanoplatforms.....	574
20.12	Newly developed hybrid nanoplatforms.....	575
20.13	Conclusion and outlook.....	576
	References.....	578
CHAPTER 21	Nanorobots for improved theranostic applications.....	587
	<i>Nigar Anzar, Neelam Yadav and Jagriti Narang</i>	
21.1	Introduction.....	587
21.2	What are nanorobots?.....	588
21.3	Fabrication/design of nanorobots.....	590
21.4	Actuation methods.....	591
	21.4.1 Physical actuation.....	591
	21.4.2 Chemical actuation.....	593
21.5	Locomotion.....	594
21.6	Motion control and navigation.....	596
21.7	Classification of nanorobots.....	597
	21.7.1 Nanomanipulators.....	597
	21.7.2 Bio nanorobots (DNA and protein-based robotic systems).....	598
	21.7.3 Bacteria based nanorobots.....	599
	21.7.4 Magnetic nanorobots.....	599

21.7.5	Applications of nanorobots in therapeutics.....	600
21.8	Conclusion and future prospects.....	605
	Acknowledgments	605
	Conflict of interest.....	605
	References.....	605
CHAPTER 22	Nanoghosts for therapeutic applications.....	613
	<i>Mohamed S. Attia, Ekram H. Mohamed and</i>	
	<i>M.S.A. Abdel-Mottaleb</i>	
22.1	Introduction	613
22.2	Formation of nanoghosts.....	615
22.3	Characterization of nanoghosts.....	615
22.4	Source of cell membranes.....	616
	22.4.1 Nuclei noncontaining cells	617
	22.4.2 Nuclei containing cells	619
22.5	Approaches for surface chemistry	621
	22.5.1 Top-down approaches	622
22.6	Application of nanoghosts	624
	22.6.1 Delivery and targeting	624
	22.6.2 Biosensing	626
	22.6.3 Cancer phototheranostics	626
	22.6.4 Cancer nanovaccination	627
	22.6.5 Use of nanoghost in specific diseases	627
	22.6.6 The use of nanoghost in targeting and treating inflammation	633
	References.....	637
CHAPTER 23	Biomimetic nanosystems in theranostics	645
	<i>Bhasha Sharma, Shashank Shekhar, Amit Kumar and</i>	
	<i>Shreya Sharma</i>	
23.1	Introduction	645
23.2	Fabrication of biomimetic nanosystems	646
23.3	Fabrication strategies using the real cell membrane	648
23.4	Biomimetic nanosystems for the treatment of cancer.....	649
	23.4.1 Chemotherapy	649
	23.4.2 Phototherapy.....	650
	23.4.3 Immunotherapy	651
	23.4.4 Other malignancy restorative modalities.....	652
	23.4.5 Cancer imaging and detection: diagnostic imaging	653
	23.4.6 Cancer imaging and detection: cancer recognition.....	654

23.4.7	Cancer imaging and detection: imaging-guided treatment.....	655
23.5	Bacterial diseases	656
23.5.1	Targeted conveyance of antibacterial medications	656
23.5.2	Detoxification.....	657
23.5.3	Antibacterial immunization	659
23.6	Inflammatory sicknesses	660
23.6.1	Atherosclerosis	660
23.6.2	Rheumatoid arthritis inflammation.....	661
23.6.3	Diabetes.....	662
23.7	Conclusion.....	662
	References.....	663
CHAPTER 24	Nanoformulations for cardiovascular therapy	669
	<i>Riham R. Mohamed</i>	
24.1	Introduction	669
24.1.1	Solving inflammation and defective efferocytosis.....	670
24.1.2	Nanoparticles designed for cardiac regeneration	671
24.1.3	Polymeric nanoparticles.....	672
24.1.4	Targeting thrombosis	673
24.2	Natural polymers	674
24.2.1	Collagen	674
24.2.2	Chitosan.....	676
24.2.3	Alginate	676
24.3	Synthetic polymers.....	677
24.3.1	Poly(ethylene glycol).....	677
24.3.2	Polycaprolactone	678
24.3.3	Poly (lactic acid).....	678
	References.....	679
CHAPTER 25	Advanced nanoformulations for neurological therapeutics	685
	<i>Naumih M. Noah, Betty N. Mbatia and Calvin A. Omolo</i>	
25.1	Introduction	685
25.2	Biomaterials for formulating nanosystems for drug delivery across the nervous system	687
25.2.1	Polymeric nanoparticles.....	688
25.2.2	Lipid-based nanoparticles	690
25.2.3	Inorganic nanoparticles.....	694
25.3	Nanoformulations for neurological therapeutics	699
25.3.1	Passive targeting of the nervous system.....	700

25.3.2	Active targeting of the nervous system.....	702
25.4	Neurotoxicity of nanosystem	706
25.5	Conclusions and future perspectives.....	707
	References.....	708
CHAPTER 26	Advanced nanoformulations for targeting, imaging, and therapy	719
	<i>Marziyeh Fathi, Shaghayegh Aslzad, Jaleh Barar and Yadollah Omid</i>	
26.1	Introduction	719
26.2	Theranostic nanoformulation	721
26.3	Inorganic nanoparticles for theranostics	722
26.3.1	Magnetic nanoparticles	722
26.3.2	Gold nanoparticles	723
26.3.3	Copper sulfide nanoparticles	724
26.3.4	Silicon nanoparticles.....	725
26.3.5	Carbon-based nanoparticles	725
26.4	Polymeric nanoformulations	726
26.4.1	Synthetic polymer-based nanotheranostics.....	727
26.4.2	Natural polymer-based nanotheranostics.....	729
26.5	Stimuli-responsive nanotheranostics clinical usage	735
26.6	Conclusion and final remarks	736
	References.....	736
CHAPTER 27	Cell-penetrating peptide(s): Design, synthesis, and site-specific nanotheranostic applications in cancer therapy.....	745
	<i>Laxmikant Gautam, Shiv Kumar Prajapati, Priya Shrivastava and Suresh Prasad Vyas</i>	
27.1	Introduction	745
27.1.1	Role of enzyme in tumor metastasis	746
27.1.2	Proteases involved in metastasis.....	746
27.1.3	Plasminogen activator.....	747
27.2	Peptide synthesis	748
27.2.1	Solid-phase peptide synthesis	749
27.2.2	Methodologies of synthesis	750
27.2.3	Sequential synthesis	750
27.2.4	Convergent synthesis	753
27.2.5	Chemical ligation.....	753
27.2.6	Experimental events of solid-phase peptide synthesis	754

27.2.7	Applications of cell-penetrating peptide in the delivery of bioactive(s)	761
27.3	Conclusion	764
	Acknowledgment	764
	References.....	765
CHAPTER 28	Development of nanographene oxide/2-hydroxyethyl methacrylate/gelatin/alginate and nanotitanium dioxide/2-hydroxyethyl methacrylate/gelatin/alginate polymeric systems for biomedical applications	771
	<i>Marija M. Babić Radić, Marija Vukomanović, Jasmina Nikodinović-Runić and Simonida Lj. Tomić</i>	
28.1	Graphene oxide-based materials for biomedical applications.....	771
28.2	Design of hybrid polymeric hydrogels platform based on nanographene oxide, alginate, gelatin, and 2-hydroxyethyl methacrylate	779
28.2.1	Biocompatibility of GOHGA hydrogels.....	780
28.2.2	Structural characteristics of GOHGA hybrid hydrogels	780
28.2.3	Morphology of GOHGA hybrid hydrogels	782
28.2.4	Mechanical properties of GOHGA hybrid hydrogels	782
28.2.5	The porosity of GOHGA hybrid hydrogels.....	783
28.2.6	The hydrophilicity of GOHGA hydrogels.....	783
28.2.7	In vitro degradation properties of GOHGA hybrid hydrogels	783
28.2.8	Evaluation of GOHGA hybrid hydrogels as controlled drug release systems.....	784
28.3	Titanium dioxide-based materials for biomedical applications.....	787
28.4	Design of hybrid polymeric hydrogels platform based on nanotitanium dioxide, alginate, gelatin, and 2-hydroxyethyl methacrylate	791
28.4.1	Biocompatibility of TiHGA hybrid hydrogels	791
28.4.2	Structural characteristics of TiHGA hybrid hydrogels	792
28.4.3	Morphology of TiHGA hybrid hydrogels	793
28.4.4	Mechanical properties of TiHGA hybrid hydrogels.....	794
28.4.5	The porosity of TiHGA hybrid hydrogels.....	795
28.4.6	The hydrophilicity of TiHGA hybrid hydrogels	795

28.4.7 In vitro degradation properties of TiHGA hybrid hydrogels	795
28.5 Summary and future perspectives.....	796
28.6 GOHGA hybrid hydrogels	798
28.7 TiHGA hybrid hydrogels	799
Acknowledgments	799
References.....	800
References.....	811

Advanced nanoformulations for theranostics: current status and challenges

1

Aalok Basu¹, Md Saquib Hasnain², Amit Kumar Nayak³ and Tejraj M. Aminabhavi⁴

¹*Department of Pharmaceutics, Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, Durgapur, West Bengal, India*

²*Department of Pharmacy, Palamau Institute of Pharmacy, Daltonganj, Jharkhand, India*

³*Department of Pharmaceutics, Seemanta Institute of Pharmaceutical Sciences, Mayurbhanj, Odisha, India*

⁴*School of Advanced Sciences, KLE Technological Sciences, Hubballi, Karnataka, India*

1.1 Introduction

Theranostic is described as a platform that combines the modalities of diagnostic imaging as well as therapy and hence, increases the precision and effectiveness of a particular treatment (Kim, Kwak, Kim, Yoon, & Kwon, 2019; Tade & Patil, 2020). The concept of theranostics was introduced by John Funkhouser way back in 2002 (Jeelani et al., 2014). Since then, this innovative platform has helped to overcome the gap between biodistribution as well as the specificity of therapeutic agents and imaging molecules. Theranostics comprise a single delivery vector, which can deliver therapeutic and diagnostic agents at the same dose in the desired cellular environment (Filippi, Chiaravalloti, Schillaci, Cianni, & Bagni, 2020; Jeelani et al., 2014; Vahidfar, Aghanejad, Ahmadzadehfah, Farzanehfah, & Eppard, 2021).

Before starting the treatment of a particular disease, it is essential to understand the cellular phenotypes and tissue heterogeneity. Each disease exhibits certain features, which may be intelligently used to execute payload delivery at the intended site. Tumor tissues, for example, possess several unique traits including acidic pH, hypoxia, and higher enzymatic activities. Therefore a formulation chemist may prefer the use of complementary innovations such as pH-responsive materials or redox-sensitive polymers to ensure the delivery of drugs or diagnostics within the tumor microenvironment (Uthaman, Huh, & Park, 2018). The objective of theranostics is to image as well as monitor the diseased tissues, drug release kinetics, and therapeutic efficacy, which ultimately exert the perfect control on patient therapy (Jeelani et al., 2014). Customizing medicines, rather than implementing a generalized approach, can push the field of nanomedicines toward an era of advanced therapeutics and personalized treatments (Kim, Lee, & Chen, 2013; Mura & Couvreur, 2012).